Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sorafenib showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sorafenib probably leads to higher progression‐free survival (absolute effect size estimates based on… compared with pazopanib (targeted agent versus targeted agent) (moderate certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sorafenib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with pazopanib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with pazopanib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review
Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes overall survival (absolute effect size estimates based on survival… compared with sunitinib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review
Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib may leads to lower progression‐free survival (absolute effect size estimates based on… compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review